| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
c-Met-IN-15 targets c-Met kinase, a receptor tyrosine kinase involved in various cellular processes including cell proliferation, survival, and migration. By inhibiting c-Met kinase activity, it blocks the downstream signaling pathways that promote tumor cell growth and metastasis. This makes it a valuable tool for studying the role of c-Met in cancer and other diseases.
|
|---|---|
| ln Vitro |
In vitro, c-Met-IN-15 has been shown to inhibit c-Met kinase activity by 21.1% at a concentration of 10 μM. Its inhibitory activity is assessed using biochemical kinase assays that measure the phosphorylation of a substrate in the presence of the compound. These studies confirm its potential as a c-Met inhibitor.
|
| ln Vivo |
In vivo activity of c-Met-IN-15 is not extensively documented. As a research compound with modest inhibitory activity (21.1% at 10 μM), its primary use is in cell-free and cellular assays to study c-Met biochemistry. Its effects in animal models would need to be further investigated.
|
| Enzyme Assay |
Cell-free assays for c-Met-IN-15 typically involve measuring its inhibitory activity against c-Met kinase using a biochemical kinase assay. The compound's inhibition rate of 21.1% at 10 μM is determined by measuring the phosphorylation of a peptide substrate in the presence of the inhibitor. These assays are used to characterize the compound's potency.
|
| Cell Assay |
In vitro cellular assays are conducted to evaluate the functional activity of c-Met-IN-15. Cancer cell lines expressing c-Met are treated with the compound. c-Met phosphorylation is measured to assess the inhibition of kinase activity. Cell proliferation and migration assays are used to evaluate the compound's effects on c-Met-mediated cellular processes.
|
| Animal Protocol |
In vivo animal experiments are not typically performed with c-Met-IN-15 as a primary research focus, given its modest potency. However, its effects could be studied in animal models of cancer if higher concentrations or formulations are used. Such studies would involve administering the compound and monitoring tumor growth or relevant biomarkers.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of c-Met-IN-15 are typical of a small molecule inhibitor. Its molecular weight is 299.26. It is soluble in DMSO at 50 mg/mL. While detailed PK parameters are not widely published, its properties suggest it is designed to have favorable drug-like characteristics for in vitro use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of c-Met-IN-15 is not extensively documented. As a research compound, standard safety precautions should be taken when handling it. Its use is restricted to research purposes and it is not intended for human consumption.
|
| References | |
| Additional Infomation |
c-Met-IN-15 is a research compound used to study c-Met kinase activity and signaling pathways. It is a valuable tool for understanding the role of c-Met in cancer and for developing potential therapeutic strategies. The compound is not approved for therapeutic use and is intended for research purposes only.
|
| Molecular Formula |
C15H10FN3O3
|
|---|---|
| Exact Mass |
299.07
|
| CAS # |
330572-32-2
|
| PubChem CID |
837637
|
| Appearance |
Orange to reddish brown solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(NN=C1C2=C(NC1=O)C=CC(F)=C2)(=O)C1=CC=C(O)C=C1
|
| InChi Key |
NBNLEALJOLHMEO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10FN3O3/c16-9-3-6-12-11(7-9)13(15(22)17-12)18-19-14(21)8-1-4-10(20)5-2-8/h1-7,17,20,22H
|
| Chemical Name |
N-[(5-fluoro-2-hydroxy-1H-indol-3-yl)imino]-4-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
